Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.21
−$0.20 · -1.92%
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Previous close
$10.21
−$0.20 · -1.92%
Pre-market
$10.4603
+$0.2503 · +2.45%
Oct 9, 5:51 AM ET
Regular session · ET · Market data may be delayed.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Day range
Current $10.21
52-week range
Current $10.21
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
71
Bullish
Risk
53
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Day range
Current $10.21
52-week range
Current $10.21
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 105K USD | — | — | — | — |
| Gross profit | −105K USD | — | — | — | — |
| Research and development | 33.72M USD | 19.39M USD | 16.53M USD | 24.47M USD | 29.12M USD |
| Selling, general, and administrative | 9.25M USD | 8.16M USD | 6.88M USD | 8.1M USD | 9.52M USD |
| Operating expenses | 42.87M USD | 27.55M USD | 23.41M USD | 32.57M USD | 38.63M USD |
| Interest income | 2.51M USD | 1.82M USD | 1.58M USD | 654K USD | — |
| Interest expense | — | — | — | — | 15K USD |
| Depreciation and amortization | 105K USD | 85K USD | 151K USD | 367K USD | 460K USD |
| Operating income | −42.97M USD | −27.55M USD | −23.41M USD | −32.57M USD | −38.63M USD |
| Net income | −15.28M USD | −62.29M USD | −27.03M USD | −41.31M USD | −43.24M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$40.00
291.77% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI33.8M0.00%2.3T USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI19.38M0.19%10.11B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM17.51M0.02%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF12.09M0.01%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO6.22M0.04%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO5.46M0.03%18B USD0.06%$112.1-0.10%
iShares Biotechnology ETFIBB5.04M0.05%10.41B USD0.44%$200.48-1.41%
Schwab U.S. Small-Cap ETFSCHA4.12M0.02%21.73B USD0.03%$32.66+0.15%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
